Free Trial

Estrella Immunopharma (ESLA) Stock Price, News & Analysis

$0.93 +0.01 (+0.93%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Estrella Immunopharma Stock (NASDAQ:ESLA)

Key Stats

Today's Range
$0.93
$0.98
50-Day Range
$0.90
$1.49
52-Week Range
$0.63
$3.23
Volume
108,011 shs
Average Volume
77,751 shs
Market Capitalization
$33.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
Consensus Rating
Buy

Company Overview

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Remove Ads

Estrella Immunopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

ESLA MarketRank™: 

Estrella Immunopharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 586th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Estrella Immunopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Estrella Immunopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Estrella Immunopharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Estrella Immunopharma is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Estrella Immunopharma is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Estrella Immunopharma has a P/B Ratio of 7.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.22% of the float of Estrella Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Estrella Immunopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Estrella Immunopharma has recently increased by 2.73%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Estrella Immunopharma does not currently pay a dividend.

  • Dividend Growth

    Estrella Immunopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.22% of the float of Estrella Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Estrella Immunopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Estrella Immunopharma has recently increased by 2.73%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Estrella Immunopharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Estrella Immunopharma this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Estrella Immunopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    55.10% of the stock of Estrella Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.35% of the stock of Estrella Immunopharma is held by institutions.

  • Read more about Estrella Immunopharma's insider trading history.
Receive ESLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

ESLA Stock News Headlines

Estrella Immunopharma completes first dose cohort in STARLIGHT trial
The Greatest "Income Opportunity" of 2025?
It has been a wild couple of months so far. And not just in the markets. In our everyday lives. For me, it's highlighted the importance of investment income you can count on…even when life becomes unpredictable. Which is why I've put together this urgent presentation.
See More Headlines

ESLA Stock Analysis - Frequently Asked Questions

Estrella Immunopharma's stock was trading at $1.20 on January 1st, 2025. Since then, ESLA shares have decreased by 22.8% and is now trading at $0.9270.
View the best growth stocks for 2025 here
.

Top institutional investors of Estrella Immunopharma include Geode Capital Management LLC (0.26%).

Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Estrella Immunopharma investors own include NuCana (NCNA), Cardio Diagnostics (CDIO), Caribou Biosciences (CRBU), GRI Bio (GRI), Intrusion (INTZ), Lonestar Resources US (LONE) and Children's Place (PLCE).

Company Calendar

Today
3/31/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ESLA
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+1,532.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.12 per share
Price / Book
8.17

Miscellaneous

Free Float
16,244,000
Market Cap
$35.44 million
Optionable
Not Optionable
Beta
0.40
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ESLA) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners